Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial.

被引：4
|
作者：
Mok, Tony
Cheng, Ying
Zhou, Xiangdong
Lee, Ki Hyeong
Nakagawa, Kazuhiko
Niho, Seiji
Tsuji, Fumito
Rosell, Rafael
Jaime, Jesus Corral
Migliorino, Maria Rita
Pluzanski, Adam
Linke, Rolf Gerhard
Sbar, Eric
Wang, Tao
Wu, Yi-Long
机构：
[1] Chinese Univ Hong Kong, Hong Kong, Peoples R China
[2] Jilin Canc Hosp, Changchun, Jilin, Peoples R China
[3] Third Mil Univ, Affiliated Hosp 1, Chongqing, Peoples R China
[4] Chungbuk Natl Univ Hosp, Chungcheong, South Korea
[5] Kinki Univ, Fac Med, Osakasayama, Japan
[6] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan
[7] SFJ Pharmaceut Grp Inc, Osaka, Japan
[8] Catalan Inst Oncol, Barcelona, Spain
[9] Hosp Virgen Rocio, Seville, Spain
[10] Azienda Osped San Camilo Forlanini, Rome, Italy
[11] Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland
[12] Inst Oncol, Warsaw, Poland
[13] SFJ Pharmaceut Inc, Pleasanton, CA USA
[14] Pfizer Inc, Collegeville, PA USA
[15] Pfizer Inc, Groton, CT 06340 USA
[16] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[17] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 18期
关键词：
D O I：
10.1200/JCO.2017.35.18_suppl.LBA9007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA9007
引用
收藏
页数：3
相关论文
共 50 条
  • [21] COMPARATIVE EFFECTIVENESS ASSESSMENT OF ERLOTINIB VERSUS GEFITINIB IN FIRST-LINE EGFR ACTIVATING MUTATION POSITIVE NON-SMALL CELL LUNG CANCER
    Schwander, B.
    de Castro Carpeno, J.
    Heigener, D. F.
    Wright, E.
    Bischoff, H. G.
    Walzer, S.
    VALUE IN HEALTH, 2011, 14 (03) : A155 - A155
  • [22] Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
    Park, Keunchil
    Tan, Eng-Huat
    O'Byrne, Ken
    Zhang, Li
    Boyer, Michael
    Mok, Tony
    Hirsh, Vera
    Yang, James Chih-Hsin
    Lee, Ki Hyeong
    Lu, Shun
    Shi, Yuankai
    Kim, Sang-We
    Laskin, Janessa
    Kim, Dong-Wan
    Arvis, Catherine Dubos
    Kolbeck, Arvis Karl
    Laurie, Scott A.
    Tsai, Chun-Ming
    Shahidi, Mehdi
    Kim, Miyoung
    Massey, Dan
    Zazulina, Victoria
    Paz-Ares, Luis
    LANCET ONCOLOGY, 2016, 17 (05): : 577 - 589
  • [23] Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
    Rosell, Rafael
    Carcereny, Enric
    Gervais, Radj
    Vergnenegre, Alain
    Massuti, Bartomeu
    Felip, Enriqueta
    Palmero, Ramon
    Garcia-Gomez, Ramon
    Pallares, Cinta
    Miguel Sanchez, Jose
    Porta, Rut
    Cobo, Manuel
    Garrido, Pilar
    Longo, Flavia
    Moran, Teresa
    Insa, Amelia
    De Marinis, Filippo
    Corre, Romain
    Bover, Isabel
    Illiano, Alfonso
    Dansin, Eric
    de Castro, Javier
    Milella, Michele
    Reguart, Noemi
    Altavilla, Giuseppe
    Jimenez, Ulpiano
    Provencio, Mariano
    Angel Moreno, Miguel
    Terrasa, Josefa
    Munoz-Langa, Jose
    Valdivia, Javier
    Isla, Dolores
    Domine, Manuel
    Molinier, Olivier
    Mazieres, Julien
    Baize, Nathalie
    Garcia-Campelo, Rosario
    Robinet, Gilles
    Rodriguez-Abreu, Delvys
    Lopez-Vivanco, Guillermo
    Gebbia, Vittorio
    Ferrera-Delgado, Lioba
    Bombaron, Pierre
    Bernabe, Reyes
    Bearz, Alessandra
    Artal, Angel
    Cortesi, Enrico
    Rolfo, Christian
    Sanchez-Ronco, Maria
    Drozdowskyj, Ana
    LANCET ONCOLOGY, 2012, 13 (03): : 239 - 246
  • [24] Docetaxel and gefitinib in the first-line treatment of elderly patients (≥ 70) with advanced non-small cell lung cancer (ANSCLC):: Results of phase II trial.
    Beple, G
    Williams, CC
    Chiappori, A
    Antonia, SJ
    Haura, EB
    Mahany, JJ
    Galloway, T
    Simon, GR
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 659S - 659S
  • [25] Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
    Brown, T.
    Boland, A.
    Bagust, A.
    Oyee, J.
    Hockenhull, J.
    Dundar, Y.
    Dickson, R.
    Ramani, V. S.
    Proudlove, C.
    HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 71 - 79
  • [26] Dacomitinib for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer
    Santarpia, Mariacarmela
    Menis, Jessica
    Chaib, Imane
    Cao, Maria Gonzalez
    Rosell, Rafael
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (09) : 831 - 840
  • [27] PHASE 3 RANDOMIZED STUDY (ARCHER 1050) OF 1ST-LINE DACOMITINIB VS GEFITINIB FOR ADVANCED NSCLC WITH EGFR MUTATION(S)
    Mok, T. S. K.
    Nakagawa, K.
    Rosell, R.
    Wu, Y. -L.
    Trygstad, C.
    Capizzi, R.
    DeBenedetto, R.
    Goldberg, Z.
    Wang, T.
    Antic, V.
    ANNALS OF ONCOLOGY, 2013, 24
  • [28] Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.
    Bi, Feng
    Qin, Shukui
    Gu, Shanzhi
    Bai, Yuxian
    Chen, Zhendong
    Wang, Zishu
    Ying, Jieer
    Lu, Yinying
    Meng, Zhiqiang
    Pan, Hongming
    Yang, Ping
    Zhang, Helong
    Chen, Xi
    Xu, Aibing
    Liu, Xiufeng
    Meng, Qiu
    Wu, Liqing
    Chen, Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [29] Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial
    Yang, Yunpeng
    Min, Jie
    Yang, Nong
    Yu, Qitao
    Cheng, Ying
    Zhao, Yanqiu
    Li, Manxiang
    Chen, Hong
    Ren, Shouan
    Zhou, Jianying
    Zhuang, Wu
    Qin, Xintian
    Cao, Lejie
    Yu, Yan
    Zhang, Jian
    He, Jianxing
    Feng, Jifeng
    Yu, Hao
    Zhang, Li
    Fang, Wenfeng
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 8 (01)
  • [30] Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial
    Yunpeng Yang
    Jie Min
    Nong Yang
    Qitao Yu
    Ying Cheng
    Yanqiu Zhao
    Manxiang Li
    Hong Chen
    Shou’an Ren
    Jianying Zhou
    Wu Zhuang
    Xintian Qin
    Lejie Cao
    Yan Yu
    Jian Zhang
    Jianxing He
    Jifeng Feng
    Hao Yu
    Li Zhang
    Wenfeng Fang
    Signal Transduction and Targeted Therapy, 8
12345